NCT06627751View on ClinicalTrials.gov

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2030

Conditions
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
BIOLOGICAL

Mezigdomide

Given PO

DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Computed Tomography Assisted Biopsy

Undergo CT guided tumor Biopsy

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Biospecimen Collection

Undergo blood and saliva sample collection

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER